Skip to main content

Table 1 Clinicopathological features and tumor marker expressions in a cohort of 187 invasive breast cancer patients

From: Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis

Parameter

Total, n

(%)

Age at diagnosis

  

   Median (range)

50 years

(24-83)

Tumor size

  

   ≤ 2 cm

77

(41)

   > 2 cm

110

(59)

Nodal status

  

   Negative

71

(41)

   Positive

101

(59)

Tumor grade

  

   1

31

(17)

   2

87

(46)

   3

69

(37)

Histologic tumor type

  

   IDC (NOS)

150

(80)

   Other histologic type

37

(20)

PVI

  

   Absent

114

(66)

   Present

59

(34)

NPI

  

   Good (≤ 3.4)

49

(26)

   Moderate (3.4-5.4)

88

(47)

   Poor (> 5.4)

50

(27)

ER status

  

   Negative (≤ 10%)

53

(29)

   Positive (> 10%)

131

(71)

PR status

  

   Negative (≤ 10%)

76

(42)

   Positive (> 10%)

107

(58)

MIB1

  

   Negative (≤ 20%)

79

(43)

   Positive (> 20%)

104

(57)

HER2 status

  

   Negative

133

(85)

   Positive

23

(15)

Cytoplasmic NHERF1

  

   Negative (≤ 40%)

105

(69)

   Positive (> 40%)

47

(31)

Membranous NHERF1

  

   Negative (0%)

134

(87)

   Positive (> 0%)

20

(13)

VEGFR1

  

   Negative (≤ 2%)

82

(50)

   Positive (> 2%)

82

(50)

HIF-1α

  

   Negative (0%)

98

(63)

   Positive (> 0%)

58

(37)

TWIST1

  

   Negative (≤ 3%)

69

(49)

   Positive (> 3%)

73

(51)

  1. Abbreviations: Tumor grade = histological differentiation grade;
  2. IDC (NOS) invasive ductal carcinoma (not otherwise specified);
  3. PVI = peritumoral vascular invasion;
  4. NPI = Nottingham Prognostic Index;
  5. ER = estrogen receptor; PR = progesterone receptor;
  6. HER2 = human epidermal growth factor receptor 2